

**REMARKS**

The above-identified application was allowed in the Office Action mailed June 2, 2003. The issue fee has not been previously paid and is being submitted concurrently with this paper.

Subsequent to the receipt of the Notice of Allowance, applicant noted that Figure 8 and the paragraph on page 2 both contained inadvertent errors. The requested amendment is submitted to correct these errors.

Applicants also noted an error in paragraph [0006] of the application as published, and have amended this paragraph accordingly as set forth above. The amendment does not add new matter; it merely corrects an error in the specification that did not form the basis for allowance of the claims.

Each of the requested amendments is fully supported by the specification and drawings, will not require an additional search, and does not raise new issues. Therefore, Applicants respectfully requests that this Amendment be entered and the requested changes made.

Additionally, Applicants wish to clarify certain statements made by the Examiner in the Notice of Allowance. Specifically, the Examiner states that "[t]he instantly claimed compound, O-desmethyl venlafaxine succinate, and methods for its use, are suggested by the closest art of record, Husbands et al." Notice of Allowability, attachment, page 4.

While Applicants respectfully disagree with the Examiner's findings that Husbands suggests claimed methods for the use of ODV succinate and that the claimed compound, O-desmethylvenlafaxine succinate, is *prima facie* obvious, Applicants note that the Examiner made no such statement with respect to those claims drawn to

hydrate, polymorphic and amorphous forms of O-desmethylvenlafaxine succinate.  
Please grant any extensions of time required to enter this paper and charge any  
additional required fees to our deposit account 01-1425.

Respectfully submitted,

Dated: August 29, 2003

By: Rebecca R. Barrett  
Rebecca R. Barrett  
Reg. No. 35,152

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940-0874  
Tel. No. 610-902-2646

8/12




FIG.8